Purpose: We conducted a phase II study of combination chemotherapy with irinotecan (CPT-11) andnedaplatin (NDP), (INP regimen), to determine the effects and toxicities in patients with extensive stage smallcell lung cancer (SCLC). Methods: From March 2005 to December 2010, 60 patients with histologically orcytologically confirmed extensive SCLC were enrolled into this study. All received treatment CPT-11 at a doseof 60mg/m2 on days 1 and 8, and NDP 20mg/m2 on days1-5, every 3-4 weeks as a cycle. Patients were treateduntil tumor progression or unacceptable toxicity. Results: Main toxicities included: myelosuppression, nausea orvomiting, diarrhea, elevation of alanine aminotransferase,and bilirubin. No treatment related death occurred inthis study. Thirteen patients had complete response, forty-two had partial response, three remained stable, andtwo had progressive disease. Median progression-free survival was 13 months (95% confidence interval: 9-17)and median overall survival was 22 months (95% confidence interval: 19-25). Conclusion: INP is an effectiveand well tolerated regimen for treatment of extensive staged SCLC.
(2011). Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 12(2), 487-490.
MLA
. "Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer". Asian Pacific Journal of Cancer Prevention, 12, 2, 2011, 487-490.
HARVARD
(2011). 'Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer', Asian Pacific Journal of Cancer Prevention, 12(2), pp. 487-490.
VANCOUVER
Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2011; 12(2): 487-490.